ATE300283T1 - Propofol-formulierung - Google Patents
Propofol-formulierungInfo
- Publication number
- ATE300283T1 ATE300283T1 AT99970917T AT99970917T ATE300283T1 AT E300283 T1 ATE300283 T1 AT E300283T1 AT 99970917 T AT99970917 T AT 99970917T AT 99970917 T AT99970917 T AT 99970917T AT E300283 T1 ATE300283 T1 AT E300283T1
- Authority
- AT
- Austria
- Prior art keywords
- benzyl alcohol
- propofol formulation
- propofol
- directed
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/178,347 US6140373A (en) | 1998-10-23 | 1998-10-23 | Propofol composition |
| US09/354,017 US6140374A (en) | 1998-10-23 | 1999-07-15 | Propofol composition |
| PCT/US1999/024347 WO2000024376A1 (en) | 1998-10-23 | 1999-10-19 | Propofol composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE300283T1 true ATE300283T1 (de) | 2005-08-15 |
Family
ID=26874222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99970917T ATE300283T1 (de) | 1998-10-23 | 1999-10-19 | Propofol-formulierung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6140374A (de) |
| EP (1) | EP1124537B1 (de) |
| JP (1) | JP2002528405A (de) |
| AT (1) | ATE300283T1 (de) |
| AU (1) | AU768302B2 (de) |
| CA (1) | CA2347925C (de) |
| DE (1) | DE69926386T2 (de) |
| ES (1) | ES2245133T3 (de) |
| WO (1) | WO2000024376A1 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| DE69912441T2 (de) | 1998-08-19 | 2004-08-19 | Skyepharma Canada Inc., Verdun | Injizierbare wässerige propofoldispersionen |
| US6100302A (en) * | 1999-04-05 | 2000-08-08 | Baxter International Inc. | Propofol formulation with enhanced microbial characteristics |
| GB0012597D0 (en) * | 2000-05-25 | 2000-07-12 | Astrazeneca Ab | Formulation |
| EP1289518A2 (de) * | 2000-05-25 | 2003-03-12 | AstraZeneca AB | Pharmazeutische zusammensetzung welche ein sedatives freie radikalefangendes mittel und einen metallionen chelator enthält |
| EP1292282A2 (de) * | 2000-06-16 | 2003-03-19 | RTP Pharma Inc. | Verbesserte injektierbare propofoldispersionen |
| US6399087B1 (en) * | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| CA2459125A1 (en) | 2001-09-26 | 2003-04-03 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
| NZ534012A (en) * | 2002-01-25 | 2006-12-22 | Theravance Inc | Substituted phenylacetic acid ester compounds as short-acting sedative hypnotic agents for anesthesia and sedation |
| CA2481683A1 (en) * | 2002-04-10 | 2003-10-23 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
| JP2005529728A (ja) * | 2002-06-18 | 2005-10-06 | マーテック・バイオサイエンシーズ・コーポレーション | 水溶液中の油の安定エマルジョンおよびその製造方法 |
| US20040220283A1 (en) * | 2002-07-29 | 2004-11-04 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| BR0313060A (pt) * | 2002-07-29 | 2005-06-28 | Transform Pharmaceuticals Inc | Composições farmacêuticas aquosas de 2,6-diisopropilfenol |
| AU2003286725B2 (en) * | 2002-10-29 | 2007-07-12 | Transform Pharmaceuticals, Inc. | Propofol with cysteine |
| JP2006514994A (ja) * | 2003-03-13 | 2006-05-18 | コンフォーマ・セラピューティクス・コーポレイション | 長鎖および中鎖トリグリセリドを有する医薬製剤 |
| US20060148776A1 (en) * | 2003-03-13 | 2006-07-06 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
| US7439268B2 (en) * | 2003-07-18 | 2008-10-21 | Idexx Laboratories | Compositions containing prodrugs of florfenicol and methods of use |
| DE602004023509D1 (de) * | 2003-07-23 | 2009-11-19 | Theravance Inc | Pharmazeutische zusammensetzungen eines kurzwirkenden sedativen hypnosemittels |
| US8546453B2 (en) * | 2003-08-14 | 2013-10-01 | Rensheng Zhang | Propofol compositions and methods for reducing pain associated with propofol injection |
| US20050049210A1 (en) * | 2003-08-27 | 2005-03-03 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| EP1799266A2 (de) * | 2004-09-13 | 2007-06-27 | Bharat Serums & Vaccines Ltd. | Stabile emulsionszusammensetzungen für die intravenöse verabreichung mit antimikrobiell erhaltender wirksamkeit |
| US20060067953A1 (en) * | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
| EP1850829A4 (de) * | 2005-02-03 | 2012-12-26 | Taro Pharmaceuticals Usa Inc | Neue propofolzusammensetzung mit ascorbinsäure oder pharmazeutisch nutzbaren salzen davon |
| AU2006230447A1 (en) * | 2005-03-30 | 2006-10-05 | Conforma Therapeutics Corporation | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
| BRPI0608661A2 (pt) * | 2005-04-07 | 2010-01-19 | Conforma Therapeutics Corp | formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica |
| US20090131538A1 (en) * | 2005-05-27 | 2009-05-21 | Taro Pharmaceuticals North America, Inc. c/o Taro Pharmaceuticals U.S.A., Inc. | Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate |
| ATE420625T1 (de) * | 2005-08-05 | 2009-01-15 | Bharat Serums & Vaccines Ltd | Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt |
| CA2618799C (en) * | 2005-08-12 | 2013-06-04 | Bharat Serums & Vaccines Ltd. | Aqueous anaesthetic compositions comprising propofol |
| LT3311805T (lt) * | 2005-08-31 | 2020-04-27 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus |
| EP3527202A1 (de) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Zusammensetzungen und verfahren zur herstellung schwer wasserlöslicher arzneimittel mit erhöhter stabilität |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| JP2009518302A (ja) * | 2005-12-01 | 2009-05-07 | コンフォーマ・セラピューティクス・コーポレイション | アンサマイシン含有組成物 |
| CN101715437B (zh) * | 2007-05-09 | 2013-06-12 | 特色疗法股份有限公司 | 立体异构异丙酚治疗性化合物 |
| MY147215A (en) * | 2007-05-09 | 2012-11-14 | Pharmacofore Inc | Therapeutic compunds |
| US7550625B2 (en) * | 2007-10-19 | 2009-06-23 | Idexx Laboratories | Esters of florfenicol |
| US9132090B2 (en) | 2009-01-13 | 2015-09-15 | Chetan Majmudar | Propofol based anesthetic with preservative |
| PL2547323T3 (pl) | 2010-03-17 | 2016-07-29 | Novaliq Gmbh | Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego |
| WO2012047870A2 (en) | 2010-10-05 | 2012-04-12 | The Medicines Company | Antimicrobial preservation of propofol emulsions |
| EP2444063A1 (de) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen |
| EP2462921A1 (de) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges |
| ES2711760T3 (es) | 2011-01-04 | 2019-05-07 | Novaliq Gmbh | Emulsiones de aceite/agua que comprenden alcanos semifluorados |
| DK2714010T3 (en) | 2011-05-25 | 2017-06-12 | Novaliq Gmbh | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES |
| JP6023181B2 (ja) | 2011-05-25 | 2016-11-09 | ノバリック ゲーエムベーハー | 爪に投与するための医薬組成物 |
| KR101989648B1 (ko) | 2012-01-23 | 2019-06-14 | 노바리크 게엠베하 | 부분불소화 알칸에 기초한 안정화된 단백질 조성물 |
| AU2013314303B2 (en) | 2012-09-12 | 2018-01-18 | Novaliq Gmbh | Semifluorinated alkane compositions |
| CN113679699B (zh) | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| PT3024484T (pt) | 2013-07-23 | 2018-10-24 | Novaliq Gmbh | Composições de anticorpo estabilizadas |
| CN110403923B (zh) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| PT3442480T (pt) | 2016-06-23 | 2019-12-23 | Novaliq Gmbh | Método de administração tópica |
| CA3036297C (en) | 2016-09-22 | 2023-09-05 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| WO2018055101A1 (en) | 2016-09-23 | 2018-03-29 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP4374851B1 (de) | 2016-12-23 | 2026-04-15 | Novaliq GmbH | Ophthalmische zusammensetzung zur behandlung von trockenem auge |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| KR20200128407A (ko) | 2018-03-02 | 2020-11-12 | 노바리크 게엠베하 | 네비볼롤을 포함하는 약제학적 조성물 |
| SG11202007860XA (en) | 2018-03-28 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3923907B1 (de) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Zusammensetzungen und verfahren zur behandlung von okularer neovaskularisation |
| KR20220058577A (ko) | 2019-09-06 | 2022-05-09 | 노바리크 게엠베하 | 포도막염 치료를 위한 안과용 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798846A (en) * | 1974-03-28 | 1989-01-17 | Imperial Chemical Industries Plc | Pharmaceutical compositions |
| GB1472793A (en) * | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
| IL78929A0 (en) * | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
| US4866096A (en) * | 1987-03-20 | 1989-09-12 | Air Products And Chemicals, Inc. | Stable fluorochemical aqueous emulsions |
| JPH05170742A (ja) * | 1991-05-24 | 1993-07-09 | Ishihara Sangyo Kaisha Ltd | ジアミノトリフルオロメチルピリジン誘導体、それらの製造方法及びそれらを含有するホスホリパーゼ▲ａ２▼阻害剤 |
| JP3005275B2 (ja) * | 1990-10-18 | 2000-01-31 | 石原産業株式会社 | キヌクリジン誘導体及びその製造方法 |
| ATE155684T1 (de) * | 1992-04-28 | 1997-08-15 | Fresenius Ag | Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen |
| JP2683783B2 (ja) * | 1992-07-10 | 1997-12-03 | 雪印乳業株式会社 | シェーグレン症候群治療剤 |
| US5731356A (en) * | 1994-03-22 | 1998-03-24 | Zeneca Limited | Pharmaceutical compositions of propofol and edetate |
| GB9405593D0 (en) * | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
| AU6708096A (en) * | 1995-09-18 | 1997-04-09 | Vesifact Ag | Propofol nanodispersions |
| US5637625A (en) * | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
-
1999
- 1999-07-15 US US09/354,017 patent/US6140374A/en not_active Expired - Lifetime
- 1999-10-19 CA CA002347925A patent/CA2347925C/en not_active Expired - Fee Related
- 1999-10-19 AU AU12106/00A patent/AU768302B2/en not_active Ceased
- 1999-10-19 EP EP99970917A patent/EP1124537B1/de not_active Expired - Lifetime
- 1999-10-19 WO PCT/US1999/024347 patent/WO2000024376A1/en not_active Ceased
- 1999-10-19 DE DE69926386T patent/DE69926386T2/de not_active Expired - Lifetime
- 1999-10-19 AT AT99970917T patent/ATE300283T1/de not_active IP Right Cessation
- 1999-10-19 JP JP2000577987A patent/JP2002528405A/ja active Pending
- 1999-10-19 ES ES99970917T patent/ES2245133T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU1210600A (en) | 2000-05-15 |
| EP1124537A1 (de) | 2001-08-22 |
| US6140374A (en) | 2000-10-31 |
| CA2347925C (en) | 2009-03-17 |
| AU768302B2 (en) | 2003-12-04 |
| DE69926386T2 (de) | 2006-05-24 |
| WO2000024376A1 (en) | 2000-05-04 |
| JP2002528405A (ja) | 2002-09-03 |
| EP1124537B1 (de) | 2005-07-27 |
| DE69926386D1 (de) | 2005-09-01 |
| ES2245133T3 (es) | 2005-12-16 |
| CA2347925A1 (en) | 2000-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69926386D1 (de) | Propofol-formulierung | |
| PT1073470E (pt) | Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos | |
| BR0112030A (pt) | Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor | |
| PT750618E (pt) | Derivados de oxazolidinona e composicoes farmaceuticas que os contem | |
| CY1107992T1 (el) | Συνθεσεις πολυαμιδο-αμικου οξεος υδατικης βασεως | |
| IS6658A (is) | Ný efnasambönd | |
| MXPA05001061A (es) | Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol. | |
| BR9714270A (pt) | Composição lìquida de limpeza de pele | |
| IS6520A (is) | Ný efnasambönd | |
| BR0200782A (pt) | Compostos para o tratamento da isquemia | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
| BR0210139A (pt) | Composições farmacêuticas | |
| EA200100458A1 (ru) | Антипаразитарные препараты | |
| BRPI0113286B8 (pt) | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. | |
| EA200400432A1 (ru) | Производные мочевины | |
| BR9801652A (pt) | Resorcinil-triazinas | |
| GT199800207A (es) | Nuevos derivados de la eritromicina. | |
| BR0210028A (pt) | Agentes antibacterianos | |
| MXPA04004601A (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
| GEP20002332B (en) | Cefalosporin Derivatives | |
| WO2005072343A3 (en) | Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use | |
| SE0302139D0 (sv) | Novel compounds | |
| ATE302203T1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| CO5221025A1 (es) | 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |